Skip to content
Screener

CG Oncology CGON Q1 2025 earnings

Reported May 13, 2025 · Before market open

Revenue$52.0KMiss by $66.2K
EPS-$0.45Miss by $0.06
Revenue estimate$118.2K
EPS estimate-$0.39

Next report

Nov 13, 2026 (in 2 months)
Revenue estimate$547.7K
EPS estimate-$0.86

Financials

Q1 2025

Income statement

See full
Revenue$52.0K-90.2%
Operating income-$42.2M-87.8%
Net income-$34.5M-103%
EPS (diluted)-$0.45-25.0%

Balance sheet

See full
Cash & equivalents$41.5M-46.5%
Total debt$1.0M+156%
Total equity$704.8M+23.9%
Total assets$728.2M+25.7%

Cash flow

See full
Operating cash flow-$29.3M-12.6%
CapEx$16.0K+33.3%
Free cash flow-$29.3M-12.6%

Valuation & ratios

Valuation

as of 03/31/25
See full
Market cap$1.87B-9.7%
Enterprise value$1.83B-8.2%
P/S2,819.6×-1,014×

Profitability

See full
Operating margin-20,302.3%+31,057pp
Net margin-15,945.2%+16,679pp
FCF margin-12,419.3%—

Returns & leverage

See full
Return on equity-16.6%—
Debt / equity0×0.0×
Current ratio31×-27.0×

Segments

By product

See full
License And Collaboration Revenue$52.0K—
Commercial And Development Revenue-—

FAQ

When did CG Oncology report Q1 2025 earnings?
CG Oncology (CGON) reported Q1 2025 earnings on May 13, 2025 before market open.
What were CG Oncology's Q1 2025 revenue and EPS?
CG Oncology reported revenue of $52.0K and eps of $-0.45 for Q1 2025.
Did CG Oncology beat estimates in Q1 2025?
Revenue missed the consensus estimate of $118.2K by $66.2K. EPS missed the consensus estimate of $-0.39 by $0.06.
How did CG Oncology's Q1 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 90.2% from $529.0K a year earlier and eps declined 25.0% from $-0.36.
Where can I find CG Oncology's Q1 2025 SEC filings?
You can read the 8-K earnings release (0000950170-25-069825) and the 10-Q periodic report (0000950170-25-069831) directly on SEC EDGAR. The filing index links above go to sec.gov.